The global esophageal cancer market size is calculated at USD 16.65 billion in 2025 and is forecasted to reach around USD 34.04 billion by 2034, accelerating at a CAGR of 8.27% from 2025 to 2034. The North America market size surpassed USD 6.15 billion in 2024 and is expanding at a CAGR of 8.41% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Esophageal Cancer Market, by Cancer Type
7.1.1. Adenocarcinoma
7.1.1.1. Market Revenue and Forecast
7.1.2. Squamous Cell Carcinoma
7.1.2.1. Market Revenue and Forecast
7.1.3. Others (e.g., small cell carcinoma)
7.1.3.1. Market Revenue and Forecast
8.1. Esophageal Cancer Market, by Diagnosis
8.1.1. Endoscopy
8.1.1.1. Market Revenue and Forecast
8.1.2. Biopsy
8.1.2.1. Market Revenue and Forecast
8.1.3. Barium Swallow (Esophagram)
8.1.3.1. Market Revenue and Forecast
8.1.4. Imaging (CT, PET, MRI)
8.1.4.1. Market Revenue and Forecast
8.1.5. Esophageal Manometry
8.1.5.1. Market Revenue and Forecast
8.1.6. Blood Tests
8.1.6.1. Market Revenue and Forecast
9.1. Esophageal Cancer Market, by Treatment
9.1.1. Therapy Type
9.1.1.1. Market Revenue and Forecast
9.1.2. Drug Class
9.1.2.1. Market Revenue and Forecast
10.1. Esophageal Cancer Market, by Stage
10.1.1. Stage 0 (Carcinoma in situ)
10.1.1.1. Market Revenue and Forecast
10.1.2. Stage I
10.1.2.1. Market Revenue and Forecast
10.1.3. Stage II
10.1.3.1. Market Revenue and Forecast
10.1.4. Stage III
10.1.4.1. Market Revenue and Forecast
10.1.5. Stage IV (Metastatic)
10.1.5.1. Market Revenue and Forecast
11.1. Esophageal Cancer Market, by Route of Administration
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast
11.1.2. Intravenous
11.1.2.1. Market Revenue and Forecast
11.1.3. Others
11.1.3.1. Market Revenue and Forecast
12.1. Esophageal Cancer Market, by End User
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast
12.1.2. Specialty Cancer Centers
12.1.2.1. Market Revenue and Forecast
12.1.3. Academic & Research Institutes
12.1.3.1. Market Revenue and Forecast
12.1.4. Ambulatory Surgical Centers (ASCs) (Fastest)
12.1.4.1. Market Revenue and Forecast
12.1.5. Homecare Settings
12.1.5.1. Market Revenue and Forecast
13.1. Esophageal Cancer Market, by Distribution Channel
13.1.1. Hospital Pharmacies
13.1.1.1. Market Revenue and Forecast
13.1.2. Retail Pharmacies
13.1.2.1. Market Revenue and Forecast
13.1.3. Online Pharmacies
13.1.3.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Cancer Type
14.1.2. Market Revenue and Forecast, by Diagnosis
14.1.3. Market Revenue and Forecast, by Treatment
14.1.4. Market Revenue and Forecast, by Stage
14.1.5. Market Revenue and Forecast, by Route of Administration
14.1.6. Market Revenue and Forecast, by Distribution Channel
14.1.7. Market Revenue and Forecast, by End User
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Cancer Type
14.1.8.2. Market Revenue and Forecast, by Diagnosis
14.1.8.3. Market Revenue and Forecast, by Treatment
14.1.8.4. Market Revenue and Forecast, by Stage
14.1.8.5. Market Revenue and Forecast, by Route of Administration
14.1.8.6. Market Revenue and Forecast, by Distribution Channel
14.1.8.7. Market Revenue and Forecast, by End User
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Cancer Type
14.1.9.2. Market Revenue and Forecast, by Diagnosis
14.1.9.3. Market Revenue and Forecast, by Treatment
14.1.9.4. Market Revenue and Forecast, by Stage
14.1.9.5. Market Revenue and Forecast, by Route of Administration
14.1.9.6. Market Revenue and Forecast, by Distribution Channel
14.1.9.7. Market Revenue and Forecast, by End User
14.2. Europe
14.2.1. Market Revenue and Forecast, by Cancer Type
14.2.2. Market Revenue and Forecast, by Diagnosis
14.2.3. Market Revenue and Forecast, by Treatment
14.2.4. Market Revenue and Forecast, by Stage
14.2.5. Market Revenue and Forecast, by Route of Administration
14.2.6. Market Revenue and Forecast, by Distribution Channel
14.2.7. Market Revenue and Forecast, by End User
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Cancer Type
14.2.8.2. Market Revenue and Forecast, by Diagnosis
14.2.8.3. Market Revenue and Forecast, by Treatment
14.2.8.4. Market Revenue and Forecast, by Stage
14.2.8.5. Market Revenue and Forecast, by Route of Administration
14.2.8.6. Market Revenue and Forecast, by Distribution Channel
14.2.8.7. Market Revenue and Forecast, by End User
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Cancer Type
14.2.9.2. Market Revenue and Forecast, by Diagnosis
14.2.9.3. Market Revenue and Forecast, by Treatment
14.2.9.4. Market Revenue and Forecast, by Stage
14.2.9.5. Market Revenue and Forecast, by Route of Administration
14.2.9.6. Market Revenue and Forecast, by Distribution Channel
14.2.9.7. Market Revenue and Forecast, by End User
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Cancer Type
14.2.10.2. Market Revenue and Forecast, by Diagnosis
14.2.10.3. Market Revenue and Forecast, by Treatment
14.2.10.4. Market Revenue and Forecast, by Stage
14.2.10.5. Market Revenue and Forecast, by Route of Administration
14.2.10.6. Market Revenue and Forecast, by Distribution Channel
14.2.10.7. Market Revenue and Forecast, by End User
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Cancer Type
14.2.11.2. Market Revenue and Forecast, by Diagnosis
14.2.11.3. Market Revenue and Forecast, by Treatment
14.2.11.4. Market Revenue and Forecast, by Stage
14.2.11.5. Market Revenue and Forecast, by Route of Administration
14.2.11.6. Market Revenue and Forecast, by Distribution Channel
14.2.11.7. Market Revenue and Forecast, by End User
14.3. APAC
14.3.1. Market Revenue and Forecast, by Cancer Type
14.3.2. Market Revenue and Forecast, by Diagnosis
14.3.3. Market Revenue and Forecast, by Treatment
14.3.4. Market Revenue and Forecast, by Stage
14.3.5. Market Revenue and Forecast, by Route of Administration
14.3.6. Market Revenue and Forecast, by Distribution Channel
14.3.7. Market Revenue and Forecast, by End User
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Cancer Type
14.3.8.2. Market Revenue and Forecast, by Diagnosis
14.3.8.3. Market Revenue and Forecast, by Treatment
14.3.8.4. Market Revenue and Forecast, by Stage
14.3.8.5. Market Revenue and Forecast, by Route of Administration
14.3.8.6. Market Revenue and Forecast, by Distribution Channel
14.3.8.7. Market Revenue and Forecast, by End User
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Cancer Type
14.3.9.2. Market Revenue and Forecast, by Diagnosis
14.3.9.3. Market Revenue and Forecast, by Treatment
14.3.9.4. Market Revenue and Forecast, by Stage
14.3.9.5. Market Revenue and Forecast, by Route of Administration
14.3.9.6. Market Revenue and Forecast, by Distribution Channel
14.3.9.7. Market Revenue and Forecast, by End User
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Cancer Type
14.3.10.2. Market Revenue and Forecast, by Diagnosis
14.3.10.3. Market Revenue and Forecast, by Treatment
14.3.10.4. Market Revenue and Forecast, by Stage
14.3.10.5. Market Revenue and Forecast, by Route of Administration
14.3.10.6. Market Revenue and Forecast, by Distribution Channel
14.3.10.7. Market Revenue and Forecast, by End User
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Cancer Type
14.3.11.2. Market Revenue and Forecast, by Diagnosis
14.3.11.3. Market Revenue and Forecast, by Treatment
14.3.11.4. Market Revenue and Forecast, by Stage
14.3.11.5. Market Revenue and Forecast, by Route of Administration
14.3.11.6. Market Revenue and Forecast, by Distribution Channel
14.3.11.7. Market Revenue and Forecast, by End User
14.4. MEA
14.4.1. Market Revenue and Forecast, by Cancer Type
14.4.2. Market Revenue and Forecast, by Diagnosis
14.4.3. Market Revenue and Forecast, by Treatment
14.4.4. Market Revenue and Forecast, by Stage
14.4.5. Market Revenue and Forecast, by Route of Administration
14.4.6. Market Revenue and Forecast, by Distribution Channel
14.4.7. Market Revenue and Forecast, by End User
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Cancer Type
14.4.8.2. Market Revenue and Forecast, by Diagnosis
14.4.8.3. Market Revenue and Forecast, by Treatment
14.4.8.4. Market Revenue and Forecast, by Stage
14.4.8.5. Market Revenue and Forecast, by Route of Administration
14.4.8.6. Market Revenue and Forecast, by Distribution Channel
14.4.8.7. Market Revenue and Forecast, by End User
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Cancer Type
14.4.9.2. Market Revenue and Forecast, by Diagnosis
14.4.9.3. Market Revenue and Forecast, by Treatment
14.4.9.4. Market Revenue and Forecast, by Stage
14.4.9.5. Market Revenue and Forecast, by Route of Administration
14.4.9.6. Market Revenue and Forecast, by Distribution Channel
14.4.9.7. Market Revenue and Forecast, by End User
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Cancer Type
14.4.10.2. Market Revenue and Forecast, by Diagnosis
14.4.10.3. Market Revenue and Forecast, by Treatment
14.4.10.4. Market Revenue and Forecast, by Stage
14.4.10.5. Market Revenue and Forecast, by Route of Administration
14.4.10.6. Market Revenue and Forecast, by Distribution Channel
14.4.10.7. Market Revenue and Forecast, by End User
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Cancer Type
14.4.11.2. Market Revenue and Forecast, by Diagnosis
14.4.11.3. Market Revenue and Forecast, by Treatment
14.4.11.4. Market Revenue and Forecast, by Stage
14.4.11.5. Market Revenue and Forecast, by Route of Administration
14.4.11.6. Market Revenue and Forecast, by Distribution Channel
14.4.11.7. Market Revenue and Forecast, by End User
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Cancer Type
14.5.2. Market Revenue and Forecast, by Diagnosis
14.5.3. Market Revenue and Forecast, by Treatment
14.5.4. Market Revenue and Forecast, by Stage
14.5.5. Market Revenue and Forecast, by Route of Administration
14.5.6. Market Revenue and Forecast, by Distribution Channel
14.5.7. Market Revenue and Forecast, by End User
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Cancer Type
14.5.8.2. Market Revenue and Forecast, by Diagnosis
14.5.8.3. Market Revenue and Forecast, by Treatment
14.5.8.4. Market Revenue and Forecast, by Stage
14.5.8.5. Market Revenue and Forecast, by Route of Administration
14.5.8.6. Market Revenue and Forecast, by Distribution Channel
14.5.8.7. Market Revenue and Forecast, by End User
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Cancer Type
14.5.9.2. Market Revenue and Forecast, by Diagnosis
14.5.9.3. Market Revenue and Forecast, by Treatment
14.5.9.4. Market Revenue and Forecast, by Stage
14.5.9.5. Market Revenue and Forecast, by Route of Administration
14.5.9.6. Market Revenue and Forecast, by Distribution Channel
14.5.9.7. Market Revenue and Forecast, by End User
15.1. F. Hoffmann-La Roche Ltd
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Merck & Co., Inc.
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. AstraZeneca plc
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Novartis AG
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Amgen Inc.
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Daiichi Sankyo Company, Limited
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Bayer AG
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Takeda Pharmaceutical Company Limited
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Illumina, Inc. (diagnostics)
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Thermo Fisher Scientific Inc. (diagnostics)
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description